Company / R&D per Share
ARDELYX, INC. R&D per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$0.29
FY2025
5-year range
$0.15 / $0.97
FY2021-FY2025
Trend
+33.2%
vs FY2024
Sector context
#187 of 208
Health Care
What the data says
Among 208 Health Care companies, ARDELYX, INC. is in the bottom 10% for r&d per share. R&D per Share has fluctuated over the past 10 years, ranging from $0.15 in FY2023 to $1.46 in FY2018.
Based on SEC 10-K filings.
0.29 in FY2025 with a 5-year CAGR of -16.8%.
Improved from $0.15 to $0.29 over the past 2 years.
Health Care sector context is included.
R&D per Share over time
Growth rates
- 3-Year CAGR
- +2.7%
- 5-Year CAGR
- -16.8%
- 10-Year CAGR
- -
Sector benchmark
Bottom 10% in Health CareTop 90% of 208This company $0.29 Sector average $28.82
▼
-99.0% below sector average
Key checks
Key Insights
- In FY2025, r&d per share increased 33.2% year-over-year.
- Ranks #187 out of 208 companies in the Health Care sector.
- Peak r&d per share was recorded in FY2018.
- Lowest r&d per share in the period was in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.41 (distress zone, below 1.8 threshold)
- Negative profit margin: -11.7%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $0.29 | +33.2% |
| FY2024 | $0.22 | +43.8% |
| FY2023 | $0.15 | -43.5% |
| FY2022 | $0.27 | -72.2% |
| FY2021 | $0.97 | +32.9% |
| FY2020 | $0.73 | -36.1% |
| FY2019 | $1.15 | -21.4% |
| FY2018 | $1.46 | +73.1% |
| FY2017 | $0.84 | -15.5% |
| FY2016 | $1.00 | -53.5% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026